Volume 3.02 | Jan 20

Human Immunology News 3.02 January 20, 2014
Human Immunology News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HIN on Twitter
Environment, Not Genes, Plays Starring Role in Human Immune Variation
A study of twins conducted by investigators shows that our environment, more than our heredity, plays the starring role in determining the state of our immune system, the body’s primary defense against disease. This is especially true as we age, the study indicates. [Press release from Stanford Medicine discussing publication in Cell] Press Release | Abstract | Graphical Abstract
Got Cells? Rare progenitor and immune cells ready for your research.
PUBLICATIONS (Ranked by impact factor of the journal)
Safety and Survival with GVAX Pancreas Prime and Listeria monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
GVAX pancreas, granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including mesothelin. On the basis of preclinical synergy, investigators tested prime/boost vaccination with GVAX and CRS-207 in pancreatic adenocarcinoma. [J Clin Oncol] Abstract

Bee Venom Processes Human Skin Lipids for Presentation by CD1a
Using bee and wasp venom responses as a model system, scientists investigated whether venoms contain CD1-presented antigens. They show that venoms activate human T cells via CD1a proteins. [J Exp Med] Abstract

Fractalkine-CX3CR1-Dependent Recruitment and Retention of Human CD1c+ Myeloid Dendritic Cells by In Vitro-Activated Proximal Tubular Epithelial Cells
Researchers identified CD1c+ dendritic cells (DCs) as the predominant source of profibrotic transforming growth factor-β and highest expressors of the fractalkine receptor CX3CR1 within the renal DC compartment. [Kidney Int] Abstract

Selective IL-2 Responsiveness of Regulatory T Cells through Multiple Intrinsic Mechanisms Support the Use of Low-Dose IL-2 Therapy in Type-1 Diabetes
Investigators show that IL-2-dependent STAT5 activation in regulatory T cells from healthy individuals and patients with type-1 diabetes occurred at approximately ten-fold lower concentration of IL-2 than required by T memory cells or by in vitro activated T cells. [Diabetes] Abstract

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD1, PD-L1 and CTLA-4
Immune effects of dabrafenib and trametinib were evaluated in human CD4+ and CD8+ T cells from healthy volunteers, a panel of human tumor cell lines, and in vivo using a CT26 mouse model. [Clin Cancer Res] Abstract

Individuals Naturally Exposed to Lutzomyia intermedia Sand Flies Develop an IL-10-Dominant Immune Response and Are at Increased Risk of Developing Cutaneous Leishmaniasis
Scientists conducted a prospective cohort analysis to characterize the human immune response to L. intermedia saliva in 264 individuals, from an area for cutaneous leishmaniasis caused by L. braziliensis. [J Infect Dis] Abstract

Elevation of c-MYC Disrupts HLA Class II-Mediated Immune Recognition of Human B Cell Tumors
Investigators report that increased c-MYC expression has a negative effect on the ability of B cell lymphomas to functionally present Ags/peptides to CD4+ T cells. [J Immunol] Abstract

Low-Dose Anti-Thymocyte Globulin Inhibits Human B-Cell Differentiation into Antibody-Secreting Cells
Researchers studied the effect of low-dose anti-thymocyte globulin on B cell activation and differentiation to antibody-secreting cells, as this may have an effect on B cell-driven autoimmune diseases, such as pemphigus vulgaris. [Acta Derm Venereol] Abstract

CD103 Marks a Subset of Human CD34+-Derived Langerin+ Dendritic Cells which Induce T Regulatory Cells via Indoleamine 2,3-Dioxygenase-1
Researchers show that during in vitro differentiation along myeloid dendritic cell lineage CD34+ hematopoietic stem/progenitor cells acquire Indoleamine 2,3-dioxygenase 1 expression, which acts in a tolerogenic manner by inducing a population of fully functional CD4+CD25+ FOXP3+ T regulatory cells. [Exp Hematol] Abstract

Subscribe to our sister publications:
Immunology of Infectious Disease News and Immune Regulation News

Learn More: StemSpan™ Myeloid Expansion Supplement
Pathophysiology of T Follicular Helper Cells in Humans and Mice
The authors present the similarities and differences between mouse and human lymphoid organ-resident follicular helper T cells (TFH cells) and discuss the role of TFH cells in response to vaccines and in disease pathogenesis. [Nat Immunol] Abstract

Visit our reviews page to see a complete list of reviews in the human immunology research field.
Phase II Clinical Data of Peregrine Pharmaceuticals’ Bavituximab in Combination with Sorafenib Presented
Peregrine Pharmaceuticals, Inc. announced the presentation of clinical data related to the company’s immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab. [Press release from Peregrine Pharmaceuticals, Inc. discussing research presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, San Francisco] Press Release

Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process
Kite Pharma, Inc. announced presentations on the company’s rapid, six-day manufacturing process for the production of Kite’s lead product candidate, KTE-C19. [Press release from Kite Pharma, Inc. discussing research presented at Scale-Up and Manufacturing of Cell-Based Therapies IV, San Diego] Press Release

From our sponsor: Learn how ex vivo models drive progress in HIV research. Read the research profiles.
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
Johnson & Johnson announced the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine regimen. [Johnson & Johnson Services, Inc.] Press Release

Novartis Cosentyx™ Is the First IL-17 Inhibitor to Receive EU Approval for First-Line Treatment of Moderate-to-Severe Psoriasis Patients
Novartis announced that the European Commission has approved Cosentyx™ (secukinumab) as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. [Novartis AG] Press Release

New Approach, New Hope: State Investment Will Fast-Track Innovative Roswell Park Research in Ovarian Cancer
Researchers at Roswell Park Cancer Institute have received a prestigious grant of nearly $12 million from the New York State Stem Cell Science Program to develop new therapies for advanced ovarian cancer. Using an approach known as adoptive T-cell therapy, the Roswell Park team will take stem cells from patients’ blood, re-engineer them and infuse the reprogrammed cells back into those patients. [Roswell Park Cancer Institute] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW World Cord Blood Congress V and Innovative Cell Therapies
March 5-8, 2015
Monaco, Monaco

NEW Cellular Therapy 2015 – 8th International Symposium on the Clinical Use of Cellular Products
March 19-20, 2015
Erlangen, Germany

Visit our events page to see a complete list of events in the human immunology community.
NEW Director (California Institute for Regenerative Medicine)

NEW Postdoctoral Position – Inflammatory Bowel Disease (The Technical University of Denmark)

Postdoctoral Position – Cancer-Related Inflammation (Institute of Human Genetics)

Tenure-Track Assistant Professor – Pathology (Stanford University School of Medicine)

Senior Research Scientist – Immunohistochemistry (iTeos Therapeutics)

Research Scientist – Cancer Immunotherapy (iTeos Therapeutics)

Senior Medical Advisor – Inflammation & Immunology (Celgene Corporation)

Product Manager Global Marketing – Autoimmunity (Thermo Fisher Scientific)

Scientist – Recombinant Molecules and Antibodies (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Human Immunology News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Human Immunology News: Archives | Events | Contact Us